## VHL Gene and Clear Cell RCC **Key Point:** VHL (von Hippel-Lindau) gene inactivation on chromosome 3p is the hallmark genetic lesion in clear cell RCC, occurring in approximately 80–90% of sporadic cases. ### Mechanism of VHL Loss 1. **Normal VHL function:** The VHL protein acts as an E3 ubiquitin ligase that targets hypoxia-inducible factor (HIF) for degradation under normoxic conditions. 2. **When VHL is lost:** HIF accumulates, leading to constitutive upregulation of HIF-target genes (VEGF, PDGF, erythropoietin). 3. **Consequence:** Increased angiogenesis, cell proliferation, and the characteristic clear cell appearance (due to lipid and glycogen accumulation from metabolic reprogramming). ### Genetic Pathways in RCC | Genetic Alteration | Associated RCC Type | Frequency | Key Feature | | --- | --- | --- | --- | | VHL loss (3p) | Clear cell RCC | 80–90% | HIF-driven angiogenesis | | TFE3 translocation (Xp11) | Papillary RCC (pediatric) | 20–40% of pediatric | MiT family translocation | | NF2 loss (22q) | Renal oncocytoma, chromophobe RCC | Rare in ccRCC | Merlin protein dysfunction | | MET amplification (7q) | Papillary RCC (type 1) | 13% of papillary | Sporadic or hereditary | **High-Yield:** VHL inactivation is so characteristic of ccRCC that its presence is a defining feature and is exploited therapeutically with VEGF inhibitors and mTOR inhibitors. **Clinical Pearl:** Patients with hereditary VHL syndrome (autosomal dominant) have a much higher lifetime risk of developing ccRCC (approaching 100% by age 65), making surveillance essential. [cite:Robbins 10e Ch 20] 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.